Serena De Matteis Beatrice Casadei Ginevra Lolli Michele Dicataldo Francesco Barbato Elisa Dan Andrea Paccagnella Barbara Sinigaglia Clara Bertuzzi Annalisa Arcari Luca Zazzeroni Patrizia Bernuzzi Noemi Laprovitera Gianluca Storci Salvatore Nicola Bertuccio Manuela Ferracin Massimiliano Bonafè Pier Luigi Zinzani Francesca Bonifazi
10.3389/fimmu.2022.994731
Front Immunol
2022 Oct 6;13:994731.
chimeric antigen receptor (car t) exhaustion lymphoma pembrolizumab resistance senescence
CC BY
https://pubmed.ncbi.nlm.nih.gov/36275688/
Lymphoma, Large B-Cell, Diffuse / drug therapy Receptors, Chimeric Antigen / genetics Receptors, Chimeric Antigen / metabolism
Lymphoma, Large B-Cell, Diffuse / drug therapy Receptors, Chimeric Antigen / genetics Receptors, Chimeric Antigen / metabolism Case Reports Research Support, Non-U.S. Gov't Antigens, CD19 CD8-Positive T-Lymphocytes Cell- and Tissue-Based Therapy Humans Immunotherapy, Adoptive Receptors, Antigen, T-Cell Antigens, CD19 Receptors, Chimeric Antigen pembrolizumab Receptors, Antigen, T-Cell
PMC9584643
36275688
Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy
2022